



EXPRESS MAIL NO. EV335393399US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Joseph Pontillo et al.
Application No. : 10/823,497
Filed : April 13, 2004
For : GONADOTROPIN-RELEASING HORMONE RECEPTOR
ANTAGONISTS AND METHODS RELATING THERETO
Art Unit : 1624
Docket No. : 690068.555C1
Date : August 24, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents:

Attached is a copy of the official Filing Receipt received from the PTO in the above-identified application, for which issuance of a corrected Filing Receipt is respectfully requested.

There is an error with respect to the following data, which is incorrectly entered. There is an error in the address of the second inventor, which should read:

Chen Chen, San Diego, CA

The correction to be made has been marked in red on the attached copy of the Filing Receipt. Also attached is a copy of the Application Data Sheet filed April 13, 2004, in which the inventor's address is correctly provided.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Karl R. Hermanns
Registration No. 33,507

KRH:lhk

Enclosures:

Copy of Filing Receipt

Copy of Application Data Sheet filed April 13, 2004

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

510036_1.DOC

COPY

Page 1 of 2

**EXPRESS MAIL NO.
EV335393399US**

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/823,497	04/13/2004	1624	0.00	690068.555C1-		12	1

CONFIRMATION NO. 3284 ✓

00500

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC

701 FIFTH AVE

SUITE 6300

SEATTLE, WA 98104-7092

FILING RECEIPT



OC000000013073683

RECEIVED

JUN 28 2004

Seed Intellectual Property
Law Group PLLC

Date Mailed: 06/25/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Joseph Pontillo, San Diego, CANADA;

Chen Chen, San Diego, ~~CHINA~~ CA**Assignment For Published Patent Application**

Neurocrine Biosciences, Inc., San Diego, CA;

Domestic Priority data as claimed by applicantThis application is a CON of 10/211,993 08/02/2002 PAT 6,740,656
which claims benefit of 60/309,980 08/02/2001**Foreign Applications**

If Required, Foreign Filing License Granted: 06/24/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Gonadotropin-releasing hormone receptor antagonists and method relating thereto

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).